Revive Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • RVV

Stock Symbol

  • Investments
  • 5

Revive Therapeutics General Information

Description

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.

Contact Information

Formerly Known As
Mercury Capital II
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 82 Richmond Street East
  • Toronto, Ontario M5C 1P1
  • Canada
+1 (888)
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
CNQ
Vertical(s)
Corporate Office
  • 82 Richmond Street East
  • Toronto, Ontario M5C 1P1
  • Canada
+1 (888)

Revive Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Revive Therapeutics Stock Performance

As of 20-Nov-2026, Revive Therapeutics’s current market cap is $3.1M with 445M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.1M 445M 225K

Revive Therapeutics Financials Summary

As of 30-Jun-2026, Revive Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 9,238 9,238 6,132 2,334
Revenue 0 0 0 0
EBITDA (741) (741) (7,879) (4,177)
Net Income (741) (741) (7,879) (4,146)
Total Assets 199 199 150 7,765
Total Debt 0 0 49 18
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Revive Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Revive Therapeutics‘s full profile, request access.

Request a free trial

Revive Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabin
Other Pharmaceuticals and Biotechnology
Toronto, Canada
6 As of 2025

Israel

Saint-Laurent, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Revive Therapeutics Competitors (7)

One of Revive Therapeutics’s 7 competitors is One World Cannabis, a Corporate Backed or Acquired company based in Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
One World Cannabis Corporate Backed or Acquired Israel
Repare Therapeutics Formerly VC-backed Saint-Laurent, Canada
Appili Therapeutics Formerly VC-backed Halifax, Canada
ConjuChem Formerly VC-backed Montreal, Canada
Tetra Bio-Pharma Corporation Orleans, Canada
You’re viewing 5 of 7 competitors. Get the full list »

Revive Therapeutics Patents

Revive Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025019927-A1 Compositions, methods and uses of bucillamine in the treatment a victim exposed to a chemical warfare agent Inactive 27-Jul-2023
US-20250352563-A1 Method and use of psilocybin in the prevention and treatment of stroke Inactive 03-May-2022
WO-2023212812-A1 Method and use of psilocybin in the prevention and treatment of stroke Inactive 03-May-2022
WO-2023184031-A1 Method and use of bucillamine in the prevention and treatment of stroke Inactive 30-Mar-2022
CA-3175679-A1 Use of psilocybin in the treatment of neurological brain injury and migraines Pending 17-Apr-2020 A61K31/675
To view Revive Therapeutics’s complete patent history, request access »

Revive Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Revive Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Revive Therapeutics‘s full profile, request access.

Request a free trial

Revive Therapeutics Investments & Acquisitions (5)

Revive Therapeutics’s most recent deal was a Corporate Asset Purchase with DiagnaMed (Intellectual Property For Neurological And Mental Health Disorders) for . The deal was made on 31-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DiagnaMed (Intellectual Property For Neurological And Mental Health Disorders) 31-Mar-2025 Corporate Asset Purchase Buildings and Property
PharmaTher (Psilocybin-Related Intellectual Property in Toronto, Canada) 17-Feb-2021 Corporate Asset Purchase Buildings and Property
Psilocin Pharma 04-Mar-2020 Merger/Acquisition Drug Discovery
Joint Venture (Revive Therapeutics / Herman Holdings) 14-Nov-2019 Joint Venture Other Consumer Non-Durables
Mercury Capital II 06-Jan-2014 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Revive Therapeutics’s complete investments and acquisitions history, request access »

Revive Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Revive Therapeutics’s complete esg history, request access »

Revive Therapeutics FAQs

  • When was Revive Therapeutics founded?

    Revive Therapeutics was founded in 2012.

  • Where is Revive Therapeutics headquartered?

    Revive Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Revive Therapeutics?

    Revive Therapeutics has 6 total employees.

  • What industry is Revive Therapeutics in?

    Revive Therapeutics’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Revive Therapeutics a private or public company?

    Revive Therapeutics is a Public company.

  • What is Revive Therapeutics’s stock symbol?

    The ticker symbol for Revive Therapeutics is RVV.

  • What is the current market cap of Revive Therapeutics?

    The current market capitalization of Revive Therapeutics is $3.1M.

  • Who are Revive Therapeutics’s competitors?

    One World Cannabis, Repare Therapeutics, Appili Therapeutics, ConjuChem, and Tetra Bio-Pharma are some of the 7 competitors of Revive Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process